Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study

Reproductive Sciences

Volumn 21, Issue 3, 2014, Pages 363-371

  Diamond, Michael P ^a   Carr, Bruce ^b   Dmowski, W Paul ^c   Koltun, William ^d   O'Brien, Chris ^e   Jiang, Ping ^f   Burke, Joshua ^e   Jimenez, Roland ^e   Garner, Elizabeth ^f   Chwalisz, Kristof ^f  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Institute for the Study and Treatment of Endometriosis   (United States)

^d Medical Center for Clinical Research   (United States)

^e NEUROCRINE BIOSCIENCES INC   (United States)

^f ABBVIE INC   (United States)

Author keywords

elagolix; endometriosis; GnRH antagonist

Indexed keywords

CELECOXIB; CODEINE; ELAGOLIX; HYDROCODONE; IBUPROFEN; KETOROLAC; MEFENAMIC ACID; NAPROXEN; OXYCODONE; PARACETAMOL; PLACEBO;

ACNE; ADULT; ANALGESIA; ANXIETY; ARTHRALGIA; ARTICLE; BEHAVIOR DISORDER; BONE DENSITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; FEMALE; HOT FLUSH; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LAPAROSCOPY; MAJOR CLINICAL STUDY; MENORRHAGIA; MIGRAINE; MULTICENTER STUDY; NAUSEA; NUMERICAL RATING SCALE; PAIN ASSESSMENT; PELVIC PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA MYCOSIS;

ELAGOLIX; ENDOMETRIOSIS; GNRH ANTAGONIST;

ADULT; DOUBLE-BLIND METHOD; ENDOMETRIOSIS; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCARBONS, FLUORINATED; PELVIC PAIN; PYRIMIDINES;

EID: 84896879235     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113497292     Document Type: Article

References (27)

1. Carr BR. Endometriosis. Chapter 10. Schorge JO Schaffer JI Halvorson LM Hoffman B Bradshaw KD Cunningham FG, ed. New York, NY: McGraw-Hill; 2008:
2. Chapron C, Fauconnier A, Dubuisson JB, Barakat H, Vieira M, Breart G. Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease. Hum Reprod. 2003; 18 (4). 760-766
3. Vercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod. 2007; 22 (1). 266-271
4. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril. 1996; 65 (2). 299-304
5. ACOG Practice bulletin No. 51. chronic pelvic pain. Obstet Gynecol. 2004; 103 (3). 589-605
6. Treatment of pelvic pain associated with endometriosis. Fertil Steril. 2008; 90 (suppl 5). S260-S269
7. Evans S, Moalem-Taylor G, Tracey DJ. Pain and endometriosis. Pain. 2007; 132 (suppl 1). S22-S25
8. Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril. 2009; 91 (1). 32-39
9. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005; 20 (10). 2698-2704
10. Bulun SE, Cheng YH, Pavone ME, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 2010; 28 (1). 36-43
11. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006; 21 (1). 248-256
12. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006; 85 (2). 314-325
13. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003; 9 (4). 387-396
14. Batzer FR. GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006; 13 (6). 539-545
15. Olive DL. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med. 2008; 359 (11). 1136-1142
16. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?. Curr Opin Obstet Gynecol. 2010; 22 (4). 283-288
17. Fuldeore MJ, Marx SE, Chwalisz K, Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010; 26 (3). 729-736
18. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009; 15 (4). 441-461
19. Tandoi I, Somigliana E, Riparini J, Ronzoni S, Vigano P, Candiani M. High rate of endometriosis recurrence in young women. J Pediatr Adolesc Gynecol. 2011; 24 (6). 376-379
20. International conference on harmonisation of technical requirements for registation of pharmaceuticals for human use. Good Clinical Practice. http://ichgcp.net/. Accessed June 28, 2011.
21. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981; 139 (6). 645-654
22. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94 (2). 149-158
23. Jones G, Jenkinson C, Kennedy S. Development of the short form endometriosis health profile questionnaire: the EHP-5. Qual Life Res. 2004; 13 (3). 695-704
24. Struthers RS, Xie Q, Sullivan SK, et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology. 2007; 148 (2). 857-867
25. Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril. 2004; 81 (1). 149-153
26. Uemura T, Mohri J, Osada H, Suzuki N, Katagiri N, Minaguchi H. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril. 1994; 62 (2). 246-250
27. Carr B, Chwalisz K, Jimenez R, Burke J, Jiang P, O'Brien C. A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study. Fertil Steril. 2011; 96 (3). S45